RDD Europe 2009 Workshop
|
|
- Molly Poole
- 6 years ago
- Views:
Transcription
1 RDD Europe 2009 Workshop 20 May 2009, Lisbon, Portugal This file is a redacted version of the presentation used during the Workshop and is suitable for electronic distribution.
2 An Introduction to Differentiating Characteristics Achieved Through the Use of Active Compared to Passive DPI Drug Delivery Technology This workshop will highlight the differentiating characteristics of active dry powder inhaler (DPI) devices versus traditional passive DPI devices. It will include discussion on the various device design elements of devices as well as the importance of the patient s perspective. The various design elements will be discussed by comparing and contrasting different design approaches as well as through visual methods (e.g. high speed video/research video). In addition, a new DPI device design will be discussed that incorporates several design characteristics we believe have been optimized. 2
3 An Introduction to Differentiating Characteristics Achieved Through the Use of Active Compared to Passive DPI Drug Delivery Technology Workshop Objective: To provide a deepened appreciation around active vs passive DPIs as well as the importance of the patient s perspective in device design. Presenters: Rich Sitz Steve Stein Georgina Fradley Mike Needham 3
4 Agenda DPIs: An Introduction Sub-Systems of a DPI Active vs Passive Patient Perspective Commercialization Support 3M s DPI Offerings 4
5 DPIs: The Beginning A Century and a Half of DPIs First patented DPI (patent granted in 1852) Designed to maximize lung deposition while minimizing deposition in mouth No evidence of commercial success First commercially successful DPI: Fisons Spinhaler Delivered sodium cromolyn Commercialized 1971 Individual doses in capsules 5
6 DPIs: A Variety of Approaches 6
7 What Must Every DPI Do? API Delivery Performance: Measure using industry recognized methods Requirements defined by product definition, clinical performance, regulatory requirements Performance repeatability to insure commercial viability Patient Interaction: Intended and unintended use Ideally intuitive to use Stability: Meet regulatory requirements to a defined specification to enable a commercially viable shelf life 7
8 Sub-Systems Systems of a DPI Formulation: Neat drug Drug/excipient (e.g. lactose) blend Engineering powder Dose Storage and Metering: Reservoir device drug stored in reservoir and metered at time of dosing Capsule device drug stored in capsules metered at factory Blister device drug stored in blisters metered at factory Aerosolization Engine : Passive DPI: Relies solely on the energy of the patient s inhalation to aerosolize the powder. Active DPI: An energy source in addition to that of the patient s inhalation is used to aerosolize the powder. 8
9 Active Methods of Aerosolization Active DPIs transfer stored energy to the formulation to aerosolize the powder Source of Stored Energy: Battery Compressed gas Loaded spring Energy Transfer to Powder: Vibration Impaction Gas discharge Impeller Energy may be stored for the duration of the device s life (e.g. a battery) needs to be stable over that entire duration Stored energy may be created by the patient at time of use by a patient priming step or by cover opening 9
10 Dura Spiros DPI - Active Aerosolization First active DPI device in late-stage development Developed in 1990s Source of energy: battery driven motor Method of energy transfer: impeller 10
11 3M Taper Multidose DPI Neat drug contained in microstructured carrier tape Breathe-triggered spring impacts tape to aerosolize powder Holds up to 120 doses Source of energy: spring compressed by patient opening of mouthpiece cover Method of energy transfer: impaction of tape by metal spring 11
12 High speed video not included. 3M Taper Multidose DPI - Active Aerosolization High speed video: triggering mechanism 12
13 3M Drug Delivery Systems High speed video not included. Replaced with still images. 3M Taper Multidose DPI - Active Aerosolization High speed video: powder aerosolization Transmission Optical Microscope Image of Microstructure Before and After Dosing. 13
14 Nektar Pulmonary Inhaler First commercialized active DPI device Commercialized with Exubera in 2006 Source of energy: compression of piston from separate patient step Method of energy transfer: compressed air 14
15 Exubera - Active Aerosolization Blister pierced prior to delivery Patient compresses air prior to dosing Powder entrained by airflow through blister 15
16 Exubera - Active Aerosolization High speed video: powder aerosolization High speed video not included. 16
17 Other Active DPI Technologies MicroDose DPI Source of energy: battery powered piezoelectric crystal Method of energy transfer: piezoelectric vibration Oriel Therapeutics DPI Source of energy: battery powered piezopolymer Method of energy transfer: piezoelectric vibration WO2004/ Source of energy: propellant-filled canister Method of energy transfer: compressed propellant 17
18 Active Methods of Aerosolization Propellant DPIs 3M Taper DPI Device Dura Spiros DPI Nektar Pulmonary Inhaler Vectura Aspirair MicroDose DPI Oriel Therapeutics DPI Battery Propellant canister Loaded spring via patient opening mouthpiece cover Battery Battery Source of Energy Compressed air via patient priming step Compressed air via patient priming step Method of Energy Transfer to Formulation Impaction via rotating impeller Air impingement Air impingement Air impingement Impaction of API loaded tape Piezoelectric vibration Piezoelectric vibration 18
19 Passive Methods of Aerosolization Methods of Powder Entrainment: Airflow through powder container Venturi airflow Centrifugal discharge of particles from rotating powder container Method of Powder Deagglomeration: Airflow shear (e.g. due to airflow turbulence) Particle-to-surface impaction Particle-to-particle impaction 19
20 Passive Methods of Aerosolization Ordered blend formulations typically used: Micronized in respirable size range (< 5 µm) Large lactose need to entrain powder in airflow Blend often contains fine lactose to improve fine particle fraction (e.g. Zeng et al., IJP, 1998) Challenge associated with deagglomeration: Detachment of micronized drug from carrier is key challenge limiting FPF Detachment has been studied extensively in literature Nichols and Wynn (RDD 2008) demonstrated that torque for detachment is much higher for impaction than for airflow manipulation 20
21 Passive Methods of Aerosolization DPI Device Spinhaler Turbuhaler Clickhaler Diskus/Accuhaler Multihaler Aerolizer Conix Primary Method of Powder Entrainment Centrifugal Airflow through Container Airflow through Container Airflow through Container Venturi Centrifugal Airflow through Container Primary Method of Powder Deagglomeration Shear + Surface Impaction Particle-to-Surface Impaction Shear Shear Shear Shear + Surface Impaction Particle-to-Particle and Particleto-Surface Impaction 21
22 Spinhaler DPI Capsule pierced prior to inhalation Centrifugal release of powder from capsule on rotating impeller Patient airflow drives impeller rotation 22
23 High speed video not included. Spinhaler DPI - Passive Aerosolization High speed video: powder aerosolization 23
24 3M Conix DPI Cyclone-shaped blister pierced prior to inhalation Powder entrained by airflow through cyclone Particle-to-particle and particleto-surface deagglomeration method Selective release of respirable particles 24
25 3M Conix DPI - Passive Aerosolization High speed video: powder aerosolization Reverse vortex laden with respirable drug particles High speed video not included. Replaced with cyclone graphic. Primary vortex with drug & lactose 25
26 The Role of the Patient Product Requirements are met by: Device Formulation Patient Patient The patient s interface with the device is crucial to its success. Device Developer Formulation 26
27 Understanding Customer Needs Wide variety of DPI designs and modes of use Patient research conducted in 2 stages: Had patients keep diary for a week and interviewed in home Tested device design options with patients in 1:1 interviews Research conducted in US, UK and Italy Included all FDA age groups Asthma and COPD patients Respiratory nurses interviewed: Specialists who work in primary care and train other respiratory nurses Pharmaceutical Developer needs identified 27
28 Stage 1: Observing Inhalers in Use Able to gain understanding into frustrations, fit to daily lifestyle and work-arounds Learn how inhalation devices ingrain themselves into the lives of users: Must be discrete Fit in the pocket Easy to use Natural/organic mouthpiece Legible dose counter Not look medical 28
29 Stage 2: Testing Designs with Patients Top need expressed by patients: Size Easy to conceal in hand Transportability Common themes: Feedback the dose has been taken (through audible or visual indication) Intuitive to use Shape/design : like familiar designs, don t want it to look medical Other important features: Discreet: shape and audio cues also important Comfortable ergonomically shaped mouthpiece 29
30 Respiratory Nurses Opinions Top needs: Cost is a top factor, but not the sole factor (esp. for nurses) Easily concealable (and doesn t look like a medical device) = compliance Feedback so the patient (or carer) knows the dose has been taken Other points: Nurses expect to select different devices for different types of patients Make devices intuitive to use Fewer steps can be helpful If designed correctly, capsule devices can be intuitive as well 30
31 Pharmaceutical Developer Perspective Top needs: Efficacy fine particle fraction Consistent dosing Compatibility with range of formulations Important features: Simple to use (number of steps, clarity of numerals ) Robustness Secondary features: Stylish and discrete design Operation independent of orientation 31
32 Commercialization Support Product Requirements: Device Formulation Commercialization Requirements: Analytical Capabilities Tox and Clinical Supply Scale-up Regulatory Expertise Commercial Supply 32
33 3M s s DPI Offerings 3M Conix DPI: Available in disposable, reloadable and multi-dose formats Utilizes reverse-cyclone technology to increase delivery effectiveness Flexibility for a variety of applications 3M Taper Multidose DPI: Simple open, inhale, close mechanism Delivers up to 120 doses in small, pocket sized device Utilizes active aerosolization of neat API 33
34 Thank You! For more information: US: UK: 44 (0) Japan: (81)
35 Image references Slide 5 Slide 6 Slide 10 Slide 14 Slide 17 Spinhaler Direct haler Dura Spiros Spinhaler Exubera Handihaler Clickhaler Novolizer Diskus Turbohaler Twisthaler Microdose Omnihaler Aerolizer Dura Spiros Exubera Microdose 35
RDD Europe 2011 Workshop 4 May 2011
RDD Europe 2011 Workshop 4 May 2011 This file represents the slides presented on May 4, 2011 by 3M Drug Delivery Systems at the RDD Europe 2011 Conference in Berlin, Germany. Slides have been modified
More informationDry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success
3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has
More informationThe Use of Physics-Based Modeling to Better Design Drug- Device Interface. Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ
The Use of Physics-Based Modeling to Better Design Drug- Device Interface Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ Presentation Outline Physics-based modeling in pharmaceutical industry Pulmonary
More informationCase Study 1: Pharmaceutical Development of EXUBERA
Case Study 1: Pharmaceutical Development of EXUBERA Nancy Harper, PhD Research Fellow, Parenteral Development Center of Emphasis Pfizer Global R&D IPAC-RS Conference November 2006 1 EXUBERA Insulin human
More informationNEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS
NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS Douglas S. Gardenhire, Ed.D, RRT-NPS MODULE 1 Manipulate Small Volume Nebulizers by Order or Protocol 1 Objectives for Module 1 At the end of
More information2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus
2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus Patient Perspective Alpha-1 1 Foundation John W. Walsh Patient Focus Personal perspective Challenges and lessons Importance
More information040716_ANDI_VENTIS WEBSITE(new) Printout 1. HOME PAGE. Welcome to our world of Dry Powder Inhalers!
1. HOME PAGE Welcome to our world of Dry Powder Inhalers! Andi-Ventis Ltd, established in 2001 is a joint venture between Medochemie Ltd, Cyprus and Miat SpA Italy, founded to carry out the pharmaceutical
More informationPatient. Device Clinician. Safety & efficacy
Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331
More informationPulmonary deposition of inhaled drugs
Pulmonary deposition of inhaled drugs Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the last 5 years
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Poonam Sheth, PharmD, PhD, Research Scientist, Inhalation Matthew T. Marmura, Research Scientist, Inhalation Recipharm is frequently asked to help
More informationThe Novolizer s : overcoming inherent problems of dry powder inhalers
Respiratory Medicine (2004) Supplement A, S17 S21 ARTICLE IN PRESS The Novolizer s : overcoming inherent problems of dry powder inhalers Dieter Kohler* Chefarzt Innere Medizin und Pneumologie, Fachkrankenhaus
More informationAppendix M: Device Technique
Nursing Care of Dyspnea: The 6th Vital Sign in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Appendix M: Device Technique Medications: Inhalation Devices Medications come in many forms.
More informationDevice Design Similarity
Device Design Similarity Dave Parkins Director DPI Product Development PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda March 9-10, 2009 Device Similarity
More informationCOPD Device Workshop. Summary. Role of inhaler device in COPD. Why use inhaler device in COPD?
Part 1 Role of inhaler device in COPD COPD Device Workshop Dr Philip Lee Respiratory and Sleep Physician St George Hospital, Sydney Part 2 Part 3 Part 4 Incorrect inhaler technique-adverse clinical outcomes
More informationPerformance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI
3M Drug Delivery Systems Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI Poster Reprint / Spring 2011 John Simons 1, Herbert Chiou 1, Louis Sigtermans 1, Tom Robison 1, Debra
More informationCOMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES
COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES Miriam Sanz Cermeño and Helena Maria Cabral Marques UCTF, Faculdade de Farmácia, Universidade de Lisboa, PORTUGAL 1. Introduction Inhalation
More informationInhalation devices, proper technique and cleaning
Preventing Your Symptoms and Taking Your Medications Inhalation devices, proper technique and cleaning Knowing how to use your medications properly is important because inhaled drugs are meant to get directly
More informationYour Inhaler Devices & You
1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationThe influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationInh l a t a i tional D i ev ces for the Ou O t u pat p ie i nts Dr Sunil Sharma Senior Resident
Inhalational ldevices for the Outpatients Dr Sunil Sharma Senior Resident Introduction Inhalational ltherapy allows selective treatment t tof lungs achieving high concentrations in airway minimizing systemic
More informationInstructions for Use neglected opportunity for easy, small wins?
Instructions for Use neglected opportunity for easy, small wins? Julian Dixon IPAC-RS Science Advisor Human Factors Director of Human Factors, Team Consulting Ltd Disclaimer part of this presentation describes
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical www.cirruspharm.com February 2014 INTRODUCTION Cirrus, a Kemwell company, is frequently
More informationWhat you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG
What you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG VM The authors describe the problems that arise with metered-dose and dry-powder inhalers,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
European Medicines Agency Inspections London, 16 February 2005 Doc Ref.: EMEA/CHMP/QWP/49313/2005 corr. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF
More informationDRY POWDER INHALER; SPECIAL EMPHASIS TO FORMULATION, DEVICES, CHARACTERIZATION & PROCESS VALIDATION PROTOCOL: A REVIEW
Available online on 15.05.2017 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open access to Pharmaceutical and Medical research 2011-17, publisher and licensee JDDT, This is an Open
More informationEffect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers
Effect of Rise in Simulated Inspiratory Flow Rate and Carrier Particle Size on Powder Emptying From Dry Powder Inhalers Received March 3, 2000; Accepted April 5, 2000, Published April 20, 2000 Varsha Chavan
More informationEverything for Inhalation
Everything for Inhalation Everything for Inhalation Inhalation drug product development at Hovione has a strong focus on formulation for Dry Powder Inhalers (DPI), particularly for capsule-based and reservoir-based
More informationInhaler Standards and Competency Document
Inhaler Standards and Competency Document Inhaler Standards and Competency Document Authors: Jane Scullion Respiratory Nurse Consultant University Hospitals of Leicester NHS Trust Monica Fletcher CEO of
More informationAssessing Quality of Inhaled Products And Links to Efficacy and Safety
Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, 2011 1 Outline of the Presentation
More informationUniversity of Groningen. Technology in practice Lexmond, Anne
University of Groningen Technology in practice Lexmond, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationAdapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016
Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies Julie D. Suman, Ph.D. March 29, 2016 AGENDA Regulatory Approaches for Bioequivalence (BE) Compendial Testing Vs Pharmaceutical Equivalence
More informationRespiratory. Martin Jetzer DDL27 Edinburgh December 2016
Respiratory Investigating the Effect of the Force Control Agent Magnesium Stearate in Fluticasone Propionate Dry Powder Inhaled Formulations with Single Particle Aerosol Mass Spectrometry Martin Jetzer
More informationAppendix E: Device Technique
Adult Asthma Care Guidelines for Nurses: Promoting Control of Asthma Appendix E: Device Technique Medications: Inhalation Devices Adapted with permission from The Lung Association: www.lung.ca/asthma/manage/devices.html
More informationInfluence of blender type on the performance of ternary dry powder inhaler formulations
Institute of Pharmacy Kiel University Influence of blender type on the performance of ternary dry powder inhaler formulations Mats Hertel Theoretical background Binary formulation: 1 st blending Ternary
More informationOPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER
OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser directly references
More informationGMMMG Asthma Formulary Inhaler Options August 2017
Regular Preventer Beclometasone Beclometasone Beclometasone Brand name Qvar Easi-Breathe Clenil Modulite Easyhaler Device MDI MDI DPI Strengths 50 microgram 100 microgram 200 microgram Adult asthma 2 inhalations
More informationAssessing the role of breathing simulators in OIP testing
As first AppeAred in Inhalation April 2014 www.inhalationmag.com Assessing the role of breathing simulators in OIP testing Exploring how the application of patient-representative inhalation profiles can
More informationADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY
ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. In this article,
More informationFormulation Considerations for Inhaled Products
Formulation Considerations for Inhaled Products Formulation Considerations of Inhaled Products Inhalation Therapy Nebulizers and Formulations Dry Powder Inhalers and Formulations Metered Dose Inhalers
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More information10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationUsing an Inhaler and Nebulizer
Using an Inhaler and Nebulizer Introduction An inhaler is a handheld device that is used to deliver medication directly to your airways. A nebulizer is an electric or battery powered machine that turns
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More informationDevelopment of a Dry Powder Multi-dose Inhaler using Computational Modeling
ENGINEER - Vol. XXXXII, No. 03, pp. [57-65], 2009 The Institution of Engineers, Sri Lanka Development of a Dry Powder Multi-dose Inhaler using Computational Modeling M.A.D.A.Sudeera, V.P.C.Dassanayake,
More informationUnderstanding cascade impaction and its importance for inhaler testing
Understanding cascade impaction and its importance for inhaler testing Mark Copley, Technical Sales Manager Inhalation product development is an important area of activity for the pharmaceutical sector.
More informationCAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
xxx Qualicaps CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES There is a wide range of devices available to deliver inhalation therapies, but there is increasing
More informationPocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals
Pocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals Endorsed by NHSGGC Respiratory Managed Clinical Network; June 2016 Designed by Medical Illustration Services Contents
More informationHow can I benefit most from my COPD medications?
Fact Sheet: COPD Medications and Delivery Devices How can I benefit most from my COPD medications? COPD medications can improve your symptoms. By taking the right medication at the right time, you can
More informationMetered Dose Inhaler (MDI)
Metered Dose Inhaler (MDI) If the inhaler has not been used before, a test dose should be fired into the air to prime the system. 1. Remove cap. 2. Shake well. 3. Breathe out fully. 4. Holding inhaler
More informationIVIVC in Pediatric OIPs
IPAC-RS/UF Orlando Conference 2014 March 20, 2014 IVIVC in Pediatric OIPs Herbert Wachtel Declaration of Conflicts of Interest H. Wachtel is employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
More informationMDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
More informationInhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationProcess Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations
Process Drift and it s Resolution in the Manufacture of Drug Products MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Ed Warner, Merck MMD December 2, 2010 PQRI-FDA Workshop on Process
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationThe problem with critical and non-critical inhaler errors
The problem with critical and non-critical inhaler errors Federico Lavorini MD, PhD Dept. Experimental and Clinical Medicine Careggi University Hospital Florence, Italy Presenter disclosures Federico Lavorini
More informationUniversity of Groningen. Optimisation of dry powder inhalation Boer, Anne Haaije de
University of Groningen Optimisation of dry powder inhalation Boer, Anne Haaije de IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationA multitude of devices
A multitude of devices Dr Andrew Scroop Respiratory Consultants 15 th September 2018 STEPWISE PHARMACOLOGICAL MANAGEMENT OF STABLE COPD COPD Inhalers MILD FEV 1 60 80% predicted few symptoms breathless
More informationPatient adherence to inhaled therapy A clinical perspective. Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France
Patient adherence to inhaled therapy A clinical perspective Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France 1 Disclosures Aerocrine Almirall AstraZeneca Boehringer Ingelheim
More informationRespiratory Therapy. Medical/Scientific/General Background
Respiratory Therapy Medical/Scientific/General Background Marketing Europe Dr. Rainer Jakobs PMM Europe 1 Dr. Rainer Jakobs, PMM Europe RT Medical/Scientific/General Background 2 Dr. Rainer Jakobs, PMM
More informationNovolizer Technical Aspects
Novolizer Technical Aspects Dr José Mª Negro Alvarez H.U. Virgen de la Arrixaca.. Murcia (España) a) Profesor Asociado de Alergología. Universidad de Murcia (España) a) Contents Design and function of
More informationDry powder inhalers for pulmonary drug delivery
Review Dry powder inhalers for pulmonary drug delivery HW Frijlink & AH De Boer Department of Pharmaceutical Technology and Biopharmacy, Groningen University Institute for Drug 1. Introduction 2. The target
More informationADDITIONAL TECHNOLOGIES FOR PRESSURIZED METERED DOSE INHALERS. Steve Newman Scientific Consultant Nottingham, UK
THE PRESS-AND-BREATHE pmdi ADDITIONAL TECHNOLOGIES FOR PRESSURIZED METERED DOSE INHALERS Steve Newman Scientific Consultant Nottingham, UK steve.newman@physics.org Compact, portable, convenient Asthma
More informationAdvanced Inhaler Technique. Learning Outcomes. Disclosure 1.1. Belgian Chocolate, French Champagne and Inhaled Medication: Too Good To Waste?
Advanced Inhaler Technique Learning Outcomes Describe the mechanism of different inhalers Explain how inspiratory flow can effect drug delivery for different inhalers Counsel a patient on the correct use
More informationPublic Assessment Report Scientific discussion. Flumetor (salmeterol xinafoate/fluticasone propionate) SE/H/1068/01-02/DC
Public Assessment Report Scientific discussion Flumetor (salmeterol xinafoate/fluticasone propionate) SE/H/1068/01-02/DC This module reflects the scientific discussion for the approval of Flumetor. The
More informationTaneja Ruchi et al. IRJP 2012, 3 (11) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article RECENT TRENDS IN DPI TECHNOLOGY Taneja Ruchi*, Sachdeva Vishal, Khatri Neetu, Singh Vikramjeet Seth G. L. Bihani
More informationHARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION
HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION 2 3 QUALICAPS HISTORY Over one hundred years of experience in the manufacturing and filling of hard two-piece capsules Qualicaps
More informationHuman Factors Considerations in Inhaler Innovation
Human Factors Considerations in Inhaler Innovation Julian Dixon Director of Human Factors, Team Consulting DDL 2016 07 December 2016 Team Consulting Ltd. 2016 Terminology HF: human factors the field ergonomics
More informationInvacare Aerosol Products. Stratos Aerosol Compressors Nebulizers Asthma Management
Invacare Aerosol Products Stratos Aerosol Compressors Nebulizers Asthma Management Invacare Aerosol Products Invacare is proud to offer an updated aerosol product line that includes the Stratos Compact,
More informationInternational Pharmaceutical Aerosol Consortium on Regulation and Science
International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted
More informationChapter 1 Pulmonary drug delivery
Chapter 1 Pulmonary drug delivery Pulmonary drug delivery 1.1 Introduction The respiratory tract is an attractive route for the administration of therapeutics and genomics. The past decade has been marked
More informationDisclosures. Learning Objectives 3/25/2017. Novel Inhalers for COPD and Asthma
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. Novel Inhalers for COPD and Asthma Dennis Williams, PharmD., BCPS. AE-C Associate Professor
More informationSmart asthma therapy. Patient information Spacer inhaling aid for metered-dose aerosol inhalers
FF Smart asthma therapy Patient information Spacer inhaling aid for metered-dose aerosol inhalers :: Metered-dose inhalers coordination technique In the treatment of asthma and COPD the medications are
More informationCommon Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
More informationPeak inspiratory flow through the Genuair â inhaler in patients with moderate or severe COPD
Respiratory Medicine (9) 13, 1832e1837 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Peak inspiratory flow through the Genuair â inhaler in patients with moderate or
More informationAerosol Delivery Devices
Aerosol Delivery Devices Judy Bielenda LRRT Respiratory Therapy Clinical Specialist Pediatric Asthma Education Coordinator University of Michigan C.S. Mott Children s and Von Voigtlander Women s Hospital
More informationCombination DPI DEVICES TECHNIQUES,PRIMING & CARE
Combination DPI DEVICES TECHNIQUES,PRIMING & CARE Lisa Romard, MS, RN, CPNP, ANP, AE- C Disclosures: This presentation and clinical recommendations support best available evidence from medical literature.
More informationNHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group
NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed
More informationMoving to More Realistic In Vitro Testing of OIDPs
Moving to More Realistic In Vitro Testing of OIDPs IPAC-RS/UF 2014 Conference: Orlando Inhalation Conference - Approaches in International Regulation Renishkumar Delvadia, PhD. Food and Drug Administration
More informationCOMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium
COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by
More informationPARTICLE-PARTICLE INTERACTIONS BETWEEN TAILORED MANNITOL CARRIER PARTICLES AND DRUG PARTICLES FOR INHALATION
PARTICLE-PARTICLE INTERACTIONS BETWEEN TAILORED MANNITOL CARRIER PARTICLES AND DRUG PARTICLES FOR INHALATION DOCTORAL THESIS SUBMITTED IN THE FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR IN
More informationINTRODUCTION. Asthma Drug Delivery - 1
Asthma Drug Delivery Laboratory Experiment Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, Rowan University, Department of Chemical Engineering Edited by: C. Stewart Slater
More informationI. Subject: Medication Delivery by Metered Dose Inhaler (MDI)
I. Subject: Medication Delivery by Metered Dose Inhaler (MDI) II. Policy: Aerosol medication administration by metered dose inhaler will be performed upon a physician's order by Respiratory Therapy personnel.
More informationNebuTech nebulizer from Salter. Striving to be #1 IN PATIENT SATISFACTION. To help you and your patients. easy. breathe
nebulizer from Salter To help you and your patients breathe easy Striving to be #1 IN PATIENT SATISFACTION nebulizer from Salter Let go to work for you and your patients today. Performance Versatility
More informationNovel Application of an Old Excipient L-Leucine- Improving Physical and. Aerosolization Stability of Spray Dried Amorphous DPI Formulations.
1 Novel Application of an Old Excipient L-Leucine- Improving Physical and Aerosolization Stability of Spray Dried Amorphous DPI Formulations. Nivedita Shetty 1, Dmitry Zemlyanov 2, Qi (Tony) Zhou 1 1 Department
More informationHow to Use Inhaled Medications for Asthma and COPD
How to Use Inhaled Medications for Asthma and COPD This information is not intended to diagnose health problems or to take the place of medical advice or care you receive from your physician or other health
More informationIdentification of crystalline forms suitable for inhalation in drug discovery
Identification of crystalline forms suitable for inhalation in drug discovery Valentina Diana Di Lallo Chiesi Farmaceutici - Corporate R&D Preclinical Analytics & Early Formulations Department Crystallization:
More informationTEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.
(19) TEPZZ _784 A_T (11) EP 3 17 842 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 07.06.17 Bulletin 17/23 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/439 (06.01) (21) Application number: 1197874.9
More informationDevice Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015
Device Change Management for Inhaled Products Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015 Topics to be covered Update on ISO/TC 084/WG 15: Guidelines for development of drug products- Quality
More informationDBA Design Effectiveness Awards SoloSTAR. A disposable pen injector for insulin
DBA Design Effectiveness Awards 2009 SoloSTAR A disposable pen injector for insulin Category: Sub category: Client company: Design consultancy: Product Consumer Sanofi Aventis GmbH DCA Design International
More informationHUMAN FACTORS ENGINEERING OF SELF-INJECTION DEVICES
HUMAN FACTORS ENGINEERING OF SELF-INJECTION DEVICES In this overview, Tobias Nemeth, Business Development Manager, Ypsomed Delivery Systems, provides a useful insight into human factors engineering. The
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationENDO-EZE TM GENIUS ENDODONTIC SYSTEM WHERE SAFETY MEETS EFFICIENCY
ENDO-EZE TM GENIUS ENDODONTIC SYSTEM WHERE SAFETY MEETS EFFICIENCY WHERE SAFETY MEETS EFFICIENCY Clinicians have always had to choose between reciprocation and rotary; safety and efficiency. So which do
More informationPractical Problems With Aerosol Therapy in COPD. Joseph L Rau PhD RRT FAARC
Special Articles Practical Problems With Aerosol Therapy in COPD Joseph L Rau PhD RRT FAARC Introduction Problems With Use of MDIs Synchronizing Inhalation With MDI Actuation Lack of a Dose Counter Medical
More informationTRAINING DEVICE OPPORTUNITIES AND SOLUTIONS FOR A CHANGING RESPIRATORY MARKET
TRAINING DEVICE OPPORTUNITIES AND SOLUTIONS FOR A CHANGING RESPIRATORY MARKET Building on his previous articles in ONdrugDelivery on training devices and drug delivery device education, here, Joe Reynolds,
More informationINTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS
INTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS Here, Filipa Maia, PhD, and Maria Palha, MSc, both Scientists at Hovione, report a study whose objective was to establish relationships between
More information